MMS Wins 2025 Fierce CRO Award in Client Service; CEO Dr. Uma Sharma Named CRO Champion. Learn more
Bangalore, India (June 7, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today two major promotions at its Asia headquarters, including Dr. Arunima Sen has been promoted to the position of Head, Drug Safety and Medical Writing in India, and Nandini Vijaisimha has been promoted to the position of Head, HR and Administration in India.
Canton, Mich. and Findlay, Ohio (May 1, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that they have partnered with the University of Findlay to provide online medical writing and clinical trial disclosures courses to students at the university and across the globe.
Posted April 13, 2018
MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that it has surpassed a training milestone, now with more than 700 training courses available in their learning management system. This platform offers education to all MMS colleagues across North America, Europe, India, and South Africa in a variety of formats from instructor led to self-directed sessions.
Poster November 15, 2017
MMS Holdings Inc. (MMS) announced today that it was selected by Paratek Pharmaceuticals, Inc., (NASDAQ: PRTK) to support the development of its U.S. new drug applications (NDAs) for omadacycline. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Since its selection in June, MMS has been assisting in drafting, assembling and publishing the clinical components of the omadacycline NDAs for the U.S. Food and Drug Administration (FDA) in acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Posted November 2, 2017
MMS is collaborating with the DIA for an upcoming complimentary webinar, “Optimizing the Use of Clinical Trial Disclosure Systems to Meet Complex and Evolving Global Regulatory Requirements.”
Posted on September 26, 2017
Pfizer has selected MMS Holdings Inc. (MMS), headquartered in Canton, MI, as a preferred provider for support writing plain language summaries of the results for all its Phase 2 and 3 clinical trials.
Posted June 7, 2017
Emmaus Life Sciences Inc. (Emmaus) has announced that EndariTM for the treatment of sickle cell disease (SCD) has been recommended for approval by the Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee. In a10–3 vote, the committee recognized that the overall benefit-risk profile of disease was favorable. MMS Holdings Inc. (MMS) has been providing clinical data, writing and regulatory submission support for Emmaus since 2015.
Posted March 14, 2016
MMS Holdings Inc., a specialty data-focused CRO, has announced a $1M award toward the development of a Zika vaccine. The award is being offered as data services to qualified pharmaceutical companies supporting the commercial development of a vaccine for approval in the United States and/or other global regulatory markets.
HYDERABAD (January 26, 2016) — MMS Holdings Inc. (www.mmsholdings.com) is pleased to announce the opening of a new office in Hyderabad, India. The company’s Asia headquarters are located in Bangalore, India and the company’s ability to deliver exceptional quality across all of its service offerings has resulted in steady growth for the company. According to Prasad … MMS Announces Expansion of Asia Operations In Hyderabad
Posted June 11, 2014
MMS Holdings Inc., a clinical research organization that focuses on regulatory submission support for the pharmaceutical, biotech and medical device industries, and the Wayne State University (WSU) Graduate School announced today the creation of a scientific internship program to broaden career opportunities for graduate students.
Posted August 1, 2013
MMS Holdings Inc. today announced that it has been selected to partner with Knopp Biosciences to provide best-in-class pharmacovigilance services in support of their compound, dexpramipexole.